Methods for collecting and using placenta cord blood stem cell

• US 8,329,468 B2
• Filed: 11/10/2008
• Issued: 12/11/2012
• Est. Priority Date: 05/11/2006
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Cord Blood Science Inc.
• Inventors: Takebe, Naoko
• Primary Examiner(s): Noble, Marcia S
• Application Number:
  US12/268,319
• Publication Number:
  US 20090123437A1
• Time in Patent Office: 1,492 Days
• Field of Search: 435/379, 435/378, 424/93.7
• US Class Current: 435/379
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Claims

1. A method of isolating cord blood stem cells, comprising:

providing an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is non-exsanguinated;

performing machine perfusion of the isolated mammalian placenta with a pressure mediated pulsatile flow of a perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells;

collecting the perfusate; and

isolating the cord blood stem cells from the perfusate to produce isolated cord blood stem cells.

5. The method according to claim 1, wherein performing machine perfusion is carried out under conditions sufficient to produce a mammalian placenta substantially free from cord blood stem cells.

6. The method according to claim 1, further comprising:

cooling the isolated mammalian placenta to produce a cooled mammalian placenta;

said cooling the isolated mammalian placenta being performed prior to said performing machine perfusion.

7. The method accord to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of about >

0°

to about 15°

C. prior to said performing machine perfusion.

8. The method according to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of from about >

0°

C. to about 6°

C.

9. The method according to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of from about >

0°

C. to about 15°

C. for a period of time of up to about 40 hours.

10. The method according to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of from about >

0°

C. to about 15°

C. for a period of time of from 6 to 40 hours.

11. The method according to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of from about >

0°

C. to about 15°

C. for a period of time of from 10 to 40 hours.

12. The method according to claim 6, further comprising:

maintaining the cooled isolated mammalian placenta at a temperature of from about >

0°

C. to about 15°

C. for a period of time of from 20 to 40 hours.

13. The method according to claim 6, wherein said cooling comprises placing said isolated mammalian placenta in ice.

14. The method according to claim 1, wherein the placenta is not administered or injected with an anticoagulant prior to said performing machine perfusion.

15. The method according to claim 1, wherein the perfusion solution comprises a physiologically-compatible solution comprising an anticoagulant.

16. The method according to claim 1, wherein the perfusion solution comprises one or more anticoagulants selected from the group consisting of heparin, creatine phosphate dextrose (CPDA), or a combination thereof.

17. The method according to claim 1, wherein said machine perfusion comprises perfusing via one or more of the umbilical arteries and the umbilical vein.

18. The method according to claim 17, wherein said perfusing further comprises cannulating one or more of the umbilical arteries and the umbilical vein to produce a cannulated placenta;

and placing the cannulated placenta in a closed perfusion circuit.

19. The method according to claim 18, wherein said perfusing is carried out at a pulse setting of from about 15 beats/min to about 60 beats/min.

20. The method according to claim 18, wherein said perfusing is carried out at a pulse setting of about 60 beats/min.

21. The method according to claim 19, wherein said perfusing is carried out at a systolic pressure of from about 30 min Hg to about 70 mm Hg.

22. The method according to claim 21, wherein said perfusing is carried out for a period of time of from about 15 min. to about 35 min.

23. The method according to claim 1, wherein:

said isolated cord blood stem cells from the perfusate comprise a percentage of CD133+ cells which exceeds a percentage of CD133+ cells from a control sample, wherein said control sample comprises isolated cord blood stem cells isolated by partially exsanguinating a control non-exsanguinated mammalian placenta without performing machine perfusion on said control non-exsanguinated mammalian placenta.

24. The method according to claim 23, wherein the isolated cord blood stem cells from the perfusate further comprise cells selected from the group consisting of CD34+/CD38−

cells, CD133+/CD34+ cells, CD133+/CD34−

cells, CD117+ cells, CD90+ cells, CD59+ cells, Thy1+ cells, Lin−

cells, CXCR4+ cells, ALDH^high cells, side population (SP) cells, SSEA-3+ cells, SSEA-4+ cells, TRA-1-60 cells, TRA-1-81 cells, and combinations thereof.

25. The method according to claim 23, wherein the isolated cord blood stem cells from the perfusate further comprise stem cells that can differentiate into cells other than CD34+/CD38−

cells, CD133+ cells, CD133+/CD34+ cells, CD133+/CD34−

cells, CD117+ cells, CD90+ cells, CD59+ cells, Thy1+ cells, Lin−

cells, CXCR4+ cells, ALDH^high cells, side population (SP) cells, SSEA-3+ cells, SSEA-4+ cells, TRA-1-60 cells, or TRA-1-81 cells.

26. The method according to claim 23, wherein said isolated cord blood stem cells comprise a percentage of CD133+ cells which exceeds said control percentage by a factor of between 2 and 10.

27. The method according to claim 23, wherein the isolated cord blood stem cells further comprise cells other than CD133+ cells, wherein said cells other than CD133+ cells are selected from the group consisting of stem cells from a placenta vascular bed niche, hematopoietic stem cells, mesenchymal stem cells, and combination thereof.

2. A method of isolating cord blood stem cells, comprising:

providing an isolated mammalian placenta comprising cord blood comprising cord blood stem cells, wherein said isolated mammalian placenta is partially exsanguinated to produce a volume of cord blood comprising a first population of isolated cord blood stem cells;

conducting machine perfusion of the isolated mammalian placenta with pressure mediated perfusion solution to produce a perfusate comprising cord blood comprising cord blood stem cells, wherein said machine perfusion is performed using a pump;

collecting the perfusate; and

isolating the cord blood stem cell from the perfusate to produce a second population of isolated cord blood stem cells,

wherein said second population of isolated cord blood cells has a greater percentage of CD133+ cells than said first population of isolated cord blood cells.

3. The method according to claim 2, wherein said isolated mammalian placenta has been partially exsanguinated by venipuncture.

4. The method according to claim 2, wherein said isolated mammalian placenta has been partially exsanguinated by gravity drainage.